Search results | virus

Reports

Human Papilloma Virus Partnering

The Human Papilloma Virus Partnering provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies

Respiratory Syncytial Virus Partnering

The RSV Partnering provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

M&A rumors for buyout of Achillion Pharmaceuticals by big pharma

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Bavarian Nordic: Biotechnology smallpox fighters

Bavarian Nordic is a biotechnology company developing and manufacturing therapeutics for cancer and infectious diseases.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Antibody

An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by …..

Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

Novartis

Novartis is a top pharmaceutical company based in Basel, Switzerland

Biocon: The first Indian biotech company to achieve many milestones

Biocon is an emerging biopharmaceutical enterprise that focuses on reducing the therapy costs associated with chronic diseases such as diabetes, cancer and autoimmune diseases.

Merck KgaA partnering

Merck KGaA is a top pharmaceutical company based in Darmstadt, Germany

Cubist: Partnering activity 2009-2014

Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.

Events

Sorry, your search returned no results.


Deals

Curevac bags $52 million from Bill and Melinda Gates Foundation

The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac

Genzyme and Voyager in $845 million AAV gene therapy pact

Voyager Therapeutics and Genzyme announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders

Biogen Idec enters hemophilia academic research pact

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B

Merck licenses Moderna’s RNA-based antiviral vaccines and passive immunity therapies

Moderna Therapeutics announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases

Medimmune licenses Omnis’ immuno-oncology program

MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals

Pfizer acquires Redvax, gains promising CMV vaccine candidate

Pfizer has acquired a controlling interest in Redvax

Janssen licenses Tipifarnib to EB Pharma

EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound

Cell Medica series B brings in $78 million

Cell Medica announced the closing of a £50 million Series B investment round with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management

Roche terminates interest in Inovio INO-5150 prostate cancer immunotherapy

Inovio Pharmaceuticals announced Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150

Johnson & Johnson has acquired Alios BioPharma

Johnson & Johnson announced that it has officially acquired Alios BioPharma for $1.7 billion in cash.